Popular Articles

Cyclist Tackles Amazing Feat To Raise Money For The American Lung Association
It"s not every day one wakes up and decides to ride their bike from San Francisco to Washington, D.C., but if you are Shawne Camp, anything is possible. Camp suffers from an extremely painful and rare lung disease called spontaneous pneumothorax, which can cause a sudden collapse of the lung. After enduring chest tubes, surgery to essentially glue his right lung to his chest wall and countless hours of pulmonary rehabilitation, Shawne has since made a full recovery.

Dying At Home: A Trend That Could Make Hospitals More Efficient
Hospitals across Canada are seeking ways to free up beds. University of Alberta researcher Donna Wilson has a suggestion: people should be encouraged to die at home rather than in hospital.
News of the day
Sunbeds (UV Tanning Beds), And UV Radiation Moved Up To Highest Cancer Risk Category By International Agency For Research On Cancer (IARC)
The International Agency for Research on Cancer (IARC) has moved sunbeds (UV tanning beds) up to the highest cancer risk category-group 1-"carcinogenic to humans". The use of sunlamps and sunbeds was until now classified as "probably carcinogenic to humans" (group 2A). IARC also moved ultraviolet radiation into group 1. These and other findings are revealed in a Special Report in the August edition of The Lancet Oncology, produced by Dr Fatiha El Ghissassi and her colleagues, IARC, Lyon, France, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group.
Medical Devices

Medtronic-Supported Clinical Trial Shows ICD Patients Less Likely To Develop Need For Pacing When Device Uses MVP(R) Mode

MVP® (Managed Ventricular Pacing), exclusive programming on Medtronic pacemakers, which is proven to be effective in reducing unnecessary pacing in pacemaker patients, was applied in the MVP Trial of implantable cardioverter-defibrillator (ICD) patients. Data from MVP trial, sponsored by Medtronic, Inc. (NYSE: MDT), were presented today as a late breaking clinical trial at Heart Rhythm 2009, the annual scientific sessions of the Heart Rhythm Society. MVP dramatically reduces unnecessary right ventricular pacing, meaning it does not deliver low-level pacing pulses to the heart when it is beating normally. The trial aimed to establish whether atrial-based, dual chamber, managed ventricular pacing set at 60 beats per minute (MVP mode) is equivalent or superior to standard ventricular pacing settings of 40 beats per minute in ICD patients. The primary endpoint combined all-cause mortality and heart failure hospitalizations. An independent Data Monitoring Committee recommended early closure of the trial when it was determined that there would not be conclusive results in evaluation of the study"s primary objective. Analysis of the trial"s secondary objectives showed that with programming the ICD to MVP mode, fewer patients developed the need for pacing than those whose devices were programmed with standard ventricular pacing. "Strong clinical evidence supporting the positive outcomes that MVP can have in pacemaker patients already exists," said Marshall Stanton, M.D., vice president of clinical research for the Cardiac Rhythm Disease Management business at Medtronic. "The analysis presented today shows that MVP reduces the development of the need for pacing in some ICD patients, but there is no evidence to show atrial pacing improves outcomes among this group of ICD patients." In SAVE PACe, a previous trial of pacemaker patients published in The New England Journal of Medicine, use of Medtronic MVP or Search AV+ modes was proven to dramatically reduce unnecessary right ventricular pacing. This reduction was shown to reduce the development of persistent atrial fibrillation, which is an electrical malfunction of the upper chambers of the heart (atria) that can lead to irregular heartbeats. It is the most common side effect of pacemakers; the condition can cause stroke or death. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):